The Dana-Farber Cancer Institute (DFCI) PGY2 Oncology Pharmacy Residency is a structured, 1-year postgraduate educational and training experience designed to develop advanced knowledge and skills in the delivery of pharmaceutical services to patients with cancer. Our residency provides experience in a variety of areas of clinical oncology practice, including inpatient and outpatient adult solid tumor and hematologic malignancies, stem cell transplant, palliative care, pediatric oncology, and investigational drug services. Additional clinical and educational experiences include: weekly topic discussions, grand rounds, oral chemotherapy teach, medication safety, administration, research and academia. Primary clinical sites include DFCI, Brigham and Women’s Hospital, and MCPHS University. Through these educational experiences, residents will:
Demonstrate development as a role-model for clinical pharmacists in the oncology setting.
Develop skills in the areas of pharmacy administration, disease state management, drug information, synthesis and analysis of clinical information and development of clinical care plans.
Develop various teaching styles for application in a variety of setting including experiential education, small group teaching and group lecture.
Collaborate with clinical pharmacy staff to provide educational resources for patients and practitioners.
Refine communication and time management skills.
Develop, implement and analyze data of a year long, publishable research project.
Incorporate self-directed learning and personal development through self reflection, evaluation and feedback.
Residents who successfully complete a PGY2 oncology pharmacy residency at DFCI will develop excellent clinical and administrative knowledge, patient care and communication skills and research experience to become a proficient clinical oncology pharmacy practitioner, educator and leader.
Pharm.D. degree and ASHP accredited PGY1 pharmacy residency required; Experience in oncology preferred; Pharmacists must be licensed in the Commonwealth of Massachusetts by Sep 30, 2020.
Requirements for application: PhORCAS standard application
Application Deadline: December 30, 2019
About Dana-Farber Cancer Institute
Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to our target community across the United States and throughout the world.
The mission of the Dana-Farber Cancer Institute Pharmacy Department is to provide expert pharmaceutical care to our patients as an integral member of the health care team. The Pharmacy Department also provides clinical and technical training to pharmacy students and pharmacy residents.